Results 11 to 20 of about 113,596 (299)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma [PDF]

Frontiers in Cell and Developmental Biology, 2020
Histone deacetylases (HDACs) are enzymes that play a key role in regulating gene expression by remodeling chromatin structure. An imbalance of histone acetylation caused by deregulated HDAC expression and activity is known to promote tumor progression in
Monica Phimmachanh, Jeremy Z. R. Han, Yolande E. I. O’Donnell, Sharissa L. Latham, Sharissa L. Latham, David R. Croucher, David R. Croucher   +6 more
doaj   +3 more sources

Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy. [PDF]

PLoS ONE, 2014
Mutations in the WNT/beta-catenin pathway are present in the majority of all sporadic colorectal cancers (CRCs), and histone deacetylase inhibitors induce apoptosis in CRC cells with such mutations.
Michael Bordonaro, Eric Drago, Wafa Atamna, Darina L Lazarova   +3 more
doaj   +1 more source

Macrocyclic Histone Deacetylase Inhibitors [PDF]

Current Topics in Medicinal Chemistry, 2010
Histone deacetylase inhibitors (HDACi) are an emerging class of novel anti-cancer drugs that cause growth arrest, differentiation, and apoptosis of tumor cells. In addition, they have shown promise as anti-parasitic, anti-neurodegenerative, anti-rheumatologic and immunosuppressant agents. To date, several structurally distinct small molecule HDACi have
Sandra C, Mwakwari, Vishal, Patil, William, Guerrant, Adegboyega K, Oyelere   +3 more
openaire   +2 more sources

Histone deacetylase inhibitors and transplantation [PDF]

Current Opinion in Immunology, 2007
Simply detecting the presence or absence of Foxp3, a transcription factor characteristic of naturally occurring CD4+ CD25+ regulatory T cells (Tregs), now appears of minimal value in predicting the outcome of immunologic responses, since dividing human CD4+ effector T cells can induce Foxp3 without attaining repressive functions, and additional ...
Ran, Tao, Edwin F, de Zoeten, Engin, Ozkaynak, Liqing, Wang, Bin, Li, Mark I, Greene, Andrew D, Wells, Wayne W, Hancock   +7 more
openaire   +2 more sources

Histone Deacetylase Inhibitors: A Novel Strategy for Neuroprotection and Cardioprotection Following Ischemia/Reperfusion Injury

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Ischemia/reperfusion injury is a complex molecular cascade that causes deleterious cellular damage and organ dysfunction. Stroke, sudden cardiac arrest, and acute myocardial infarction are the most common causes of ischemia/reperfusion injury without ...
Zachary Pickell, Aaron M. Williams, Hasan B. Alam, Cindy H. Hsu   +3 more
doaj   +1 more source

Histone deacetylase 2-mediated deacetylation of the Ribonuclease 1 promoter in inflamed human endothelial cells [PDF]

, 2020
Endothelial cells (ECs) function as protective barrier to separate the blood from the surrounding tissue by conducting crucial roles in regulation and maintenance of vascular homeostasis, such as control of vessel permeability or coagulation.
Bedenbender, Katrin
core   +1 more source

Pharmacogenomics and Histone Deacetylase Inhibitors [PDF]

Pharmacogenomics, 2016
The histone deacetylase inhibitor valproic acid (VPA) has been used for many decades in neurology and psychiatry. The more recent introduction of the histone deacetylase inhibitors (HDIs) belinostat, romidepsin and vorinostat for treatment of hematological malignancies indicates the increasing popularity of these agents.
Andrew Kl, Goey, Tristan M, Sissung, Cody J, Peer, William D, Figg   +3 more
openaire   +2 more sources

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas

Haematologica, 2018
Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma/leukemia. CCR4 is an important therapeutic target molecule because mogamulizumab,
Akihiro Kitadate, Sho Ikeda, Fumito Abe, Naoto Takahashi, Norio Shimizu, Kosei Matsue, Hiroyuki Tagawa   +6 more
doaj   +1 more source

Histone-Deacetylase Inhibitors for the Treatment of Cancer [PDF]

Cell Cycle, 2004
Histone deacetylase inhibitors (HDACi) are a promising new class of chemotherapeutic drug currently in early phase clinical trials. A large number of structurally diverse HDACi have been purified or synthesised that mostly inhibit the activity of all eleven class I and II HDACs.
Lindemann, Ralph K., Gabrielli, Brian G., Johnstone, Ricky W.   +2 more
openaire   +4 more sources

Inhibition of histone deacetylase as a treatment for cardiac hypertrophy [PDF]

, 2005
The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac ...
Bristow, Michael R., Long, Carlin, McKinsey, Timothy A., Olson, Eric N.   +3 more
core   +1 more source